Post-Operative Pain Management

Core Principle: Multimodal Analgesia

"Multimodal analgesia combines different classes of medications that have different pharmacological mechanisms of action, resulting in additive or synergistic effects to reduce postoperative pain and its sequelae."

• Morgan and Mikhail's Clinical Anesthesiology, 7e

Assessment of Post-Op Pain

• Use a numeric pain scale (0-10) or visual analogue scale; document periodically throughout recovery (Joint Commission mandate)
• Pain severity varies among procedures and anesthetic techniques
• Both under- and over-estimation by staff are common; the patient's own perception remains the gold standard
• Vital signs (tachycardia, hypertension, sweating) are suggestive but unreliable alone; importantly, analgesic administration can precipitate hypotension in hypovolemic patients - Barash Clinical Anesthesia, 9e

Drug Classes in Multimodal Analgesia

1. NSAIDs

• Adding NSAIDs to systemic opioids diminishes pain intensity, reduces opioid requirements, and decreases opioid side effects (PONV, sedation, urinary retention)
• Risks: GI bleeding, wound healing impairment, renal dysfunction, possible anastomotic leak risk (controversial)
• COX-2 inhibitors (e.g., celecoxib): reduce platelet dysfunction and GI bleeding vs. non-selective NSAIDs; renal effects remain a concern; cardiovascular risk in vascular surgery patients is documented
• Morgan and Mikhail's Clinical Anesthesiology, 7e

2. Acetaminophen (Paracetamol)

• Available oral, rectal, or IV (parenteral)
• Analgesic effect ~20-30% less than NSAIDs, but safer pharmacological profile
• Significantly reduces pain intensity and spares opioid consumption after orthopedic and abdominal surgery
• Works synergistically with NSAIDs; may allow NSAIDs to be reserved for breakthrough pain
• Pediatric dosing: IV 10-15 mg/kg (neonates 10 mg/kg), oral/rectal 20-30 mg/kg rectal in infants
• Morgan and Mikhail's Clinical Anesthesiology, 7e; Barash Clinical Anesthesia, 9e

3. Gabapentinoids (Gabapentin, Pregabalin)

• Single preoperative dose decreases post-op pain and opioid consumption in the first 24 h
• Optimal dose and duration are still debated; may potentially reduce incidence of chronic post-surgical pain
• Key side effects: Sedation and dizziness, especially in older adults - can increase fall risk

4. NMDA Receptor Antagonists

• Perioperative low-dose ketamine (bolus or infusion) produces significant reduction in pain, opioid consumption, and PONV
• Particularly beneficial in patients on chronic opioids (opioid-tolerant patients)

• May reduce post-op pain and opioid consumption; optimal dosing remains uncertain
• Side effects include hypotension and potentiation of neuromuscular blockade

5. IV Lidocaine

• Growing evidence supports its use as a multimodal component
• In major abdominal surgery: associated with faster return of bowel function and shorter hospital stay
• Requires continuous cardiovascular monitoring (CNS and cardiac toxicity risk); currently limited to PACU, ICU, or monitored wards
• Dosing: 1.5 mg/kg IV bolus, then 1.5-2 mg/kg/h intraoperatively, followed by 1 mg/kg/h post-op
• Morgan and Mikhail's Clinical Anesthesiology, 7e

6. Opioids

• Remain a cornerstone of surgical pain management despite efforts to minimize use
• Patient-Controlled Analgesia (PCA) provides better pain control, greater patient satisfaction, and fewer side effects vs. nurse-administered PRN dosing
• Common parenteral opioids: morphine, fentanyl, hydromorphone
• Transition to oral opioids (oxycodone, hydrocodone) combined with NSAIDs or acetaminophen as patient recovers
• Opioid prescribing should be minimized: studies show most elective surgery patients use opioids for only 2 days or fewer; many achieve adequate control with over-the-counter medications

Regional Analgesia Techniques

• Ultrasound-guided nerve blocks combined with multimodal analgesia are a "reasonable alternative to epidural analgesia for postoperative pain management in low- to moderate-risk patients" - Miller's Anesthesia, 10e

Perioperative Analgesic Adjuvants - Quick Reference

Patient-Controlled Analgesia (PCA)

• Adults: Morphine 1-2 mg q6-10 min lockout; hydromorphone 0.2-0.4 mg q6-10 min
• Pediatric (≥5 yrs): Morphine 20 mcg/kg/dose or hydromorphone 5 mcg/kg/dose; 10-min lockout
• Continuous background infusions increase respiratory depression risk - use with caution
• Morgan and Mikhail's Clinical Anesthesiology, 7e

Special Populations

Pediatric

• Regional techniques have greatly expanded in use
• Epidural: bupivacaine 0.1-0.125% or ropivacaine 0.1-0.2% + fentanyl 2-2.5 mcg/mL at 0.1-0.4 mL/kg/h
• Codeine is falling out of favor due to pharmacogenetic variability (ultra-rapid metabolizers)
• Ketorolac in neonates <21 days or <37 weeks corrected gestational age carries increased bleeding risk

Opioid-Tolerant Patients

• Standard doses are inadequate; require higher baseline doses
• Low-dose ketamine infusion is particularly beneficial in this group

Elderly

• Gabapentinoids carry higher sedation and fall risk
• Analgesic dosing should be reduced; renal function affects NSAID and opioid clearance

Opioid Stewardship

• Multimodal pain protocols to minimize opioid prescriptions
• Education on recognizing opioid abuse patterns
• Most elective surgical patients need opioids for ≤2 days post-op; many achieve control with OTC medications alone
• Enhanced recovery pathways (ERAS) incorporate opioid-sparing strategies as a standard of care
• Schwartz's Principles of Surgery, 11e

Recent Evidence (2024-2025)

• A 2025 meta-analysis (PMID 40319048) confirms multimodal analgesia significantly reduces post-hepatectomy wound pain and shortens hospital stay
• A 2025 systematic review (PMID 40937914) found epidural analgesia superior to systemic opioids for pain management after VATS (video-assisted thoracoscopic surgery)
• A 2024 network meta-analysis in British Journal of Anaesthesia (PMID 39366846) identified the most effective non-opioid adjuvants for reducing post-op opioid consumption in obese patients, supporting individualized multimodal regimens in this high-risk population